New hope for dravet syndrome: expanded access to seizure drug stiripentol
NCT ID NCT01983722
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program provides expanded access to the drug stiripentol for people aged 6 months and older with Dravet syndrome, a severe form of epilepsy. The goal is to help control seizures that do not respond to other treatments. Participants must have a confirmed diagnosis and meet safety criteria, such as no severe liver or kidney problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Stiripentol
- What this could lead to
- If successful, this program could offer a treatment option to reduce seizures in patients with Dravet syndrome who have not responded to other therapies.
- What could go wrong
- This is an expanded access program, not a formal trial, so evidence on effectiveness and safety is limited. Stiripentol may cause side effects like drowsiness or allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRAVET SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newborn screening study aims to catch rare diseases at birth
- Virtual therapy helps kids with rare epilepsy gain daily living skills
- New hope for dravet syndrome: phase 3 trial of EPX-100 aims to cut seizures
- Could a repurposed drug tame seizures in adult dravet patients?
- New hope for rare epilepsy: fenfluramine made available for dravet patients
- New hope for kids with rare seizure disorder: ION337 trial launches